Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors as a Dual Therapeutic Target for Cardiovascular and Renal Health: A Narrative Review

Sulthan Al Rashid; Inamul Hasan Madar; Iffath Misbah; Kamalakannan Dhanabalan; Rajkapoor Balasubramanian; Naina Mohamed Pakkir Maideen

doi:10.1055/s-0045-1805026

Ibnosina Journal of Medicine and Biomedical Sciences, Inhaltsverzeichnis

CC BY 4.0 · Ibnosina Journal of Medicine and Biomedical Sciences 2025; 17(01): 004-012
DOI: 10.1055/s-0045-1805026

Review Article

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors as a Dual Therapeutic Target for Cardiovascular and Renal Health: A Narrative Review

Sulthan Al Rashid

¹Department of Pharmacology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India

,

Inamul Hasan Madar

²Center for Global Health Research, Department of Radiodiagnosis, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India

,

Iffath Misbah

²Center for Global Health Research, Department of Radiodiagnosis, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India

,

Kamalakannan Dhanabalan

³Department of Pharmacy, Excel College of Pharmacy, Komarapalayam, Tamil Nadu, India

,

Rajkapoor Balasubramanian

⁴Department of Pharmacology, J.K.K. Nattraja College of Pharmacy, Komarapalayam, Tamil Nadu, India

,

Naina Mohamed Pakkir Maideen

⁵Department of Pharmacology, College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates

⁶Department of Pharmacology, Dubai Health, Dubai, United Arab Emirates

› Institutsangaben

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a groundbreaking class of oral antihyperglycemic agents for managing type 2 diabetes mellitus (T2DM), offering dual benefits in glycemic control and cardiovascular protection. These agents work by inhibiting glucose reabsorption in the kidneys, leading to glucose excretion through urine and effectively lowering blood glucose levels. Beyond their glycemic control capabilities, SGLT2 inhibitors also reduce sodium reabsorption, contributing to blood pressure reduction through natriuresis and diuresis. Remarkably, their benefits extend to renal outcomes, showing significant improvements in patients with diabetic kidney disease and chronic kidney disease, even without diabetes. The nephroprotective mechanisms of SGLT2 inhibitors are multifaceted, including the reduction of glomerular hyperfiltration, alleviation of intraglomerular pressure, and attenuation of inflammatory and fibrotic pathways in the kidneys. This comprehensive review illustrates the diverse functions of SGLT2 inhibitors, emphasizing their significant influence on the management of T2DM and their increasing importance in the treatment of renal diseases. These inhibitors have become an integral part of the current therapeutic strategies for diabetes and its associated complications.

Keywords

SGLT2 inhibitors - canagliflozin - dapagliflozin - empagliflozin - ertugliflozin - type 2 diabetes - renoprotection

Volltext

Referenzen

References
1 Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med (Lausanne) 2021; 8: 777861
2 Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol 2022; 21 (01) 83
3 Maideen NM. Drug interactions of SGLT2 inhibitors (gliflozins) involving UGT enzymes. Archives of Diabetes and Endocrine System. 2019; 2 (02) 13-16
4 Packer M. Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?. Nat Cardiovasc Res 2023; 2 (08) 705-707
5 Mahaffey KW, Jardine MJ, Bompoint S. et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 2019; 140 (09) 739-750
6 Wiviott SD, Raz I, Bonaca MP. et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380 (04) 347-357
7 Anker SD, Butler J, Filippatos G. et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial. Circulation 2021; 143 (04) 337-349
8 Zannad F, Ferreira JP, Pocock SJ. et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation 2021; 143 (04) 310-321
9 Cosentino F, Cannon CP, Cherney DZI. et al; VERTIS CV Investigators. Efficacy of ertugliflozin on heart failure–related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV Trial. Circulation 2020; 142 (23) 2205-2215
10 Spiazzi BF, Piccoli GF, Wayerbacher LF. et al. SGLT2 inhibitors, cardiovascular outcomes, and mortality across the spectrum of kidney disease: a systematic review and meta-analysis. Diabetes Res Clin Pract 2024; 218: 111933
11 Usman MS, Bhatt DL, Hameed I. et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2024; 12 (07) 447-461
12 Karagiannidis AG, Theodorakopoulou MP, Alexandrou ME. et al. Sodium-glucose co-transporter 2 inhibitors for all-cause and cardiovascular death in people with different stages of CKD: a systematic review and meta-analysis. Eur J Clin Invest 2025; 55 (02) e14335
13 Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K. SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis. Sci Rep 2023; 13 (01) 15922
14 Carvalho PEP, Veiga TMA, Simões E. et al. Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials. Clin Res Cardiol 2023; 112 (08) 1044-1055
15 Cao H, Rao X, Jia J, Yan T, Li D. Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 2023; 60 (03) 325-335
16 Felix N, Gauza MM, Teixeira L. et al. Cardiovascular outcomes of sodium-glucose cotransporter-2 inhibitors therapy in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and updated meta-analysis. Korean Circ J 2024; 54 (09) 549-561
17 Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol 2022; 21 (01) 47
18 Li N, Zhou G, Zheng Y. et al. Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis. PLoS One 2022; 17 (01) e0261986
19 Barbarawi M, Al-Abdouh A, Barbarawi O, Lakshman H, Al Kasasbeh M, Chen K. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Fail Rev 2022; 27 (03) 951-960
20 McGuire DK, Shih WJ, Cosentino F. et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021; 6 (02) 148-158
21 Li X, Zhang Q, Zhu L. et al. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol 2021; 332: 119-126
22 Lo KB, Gul F, Ram P. et al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med 2020; 10 (01) 1-10
23 Young CF, Farnoudi N, Chen J, Shubrook JH. Exploring SGLT-2 inhibitors: benefits beyond the glucose-lowering effect—what is new in 2023?. Endocrines 2023; 4 (03) 630-655
24 Huang Y, Jiang Z, Wei Y. Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a meta-analysis of randomized controlled trials. Exp Ther Med 2021; 21 (04) 382
25 Edwards K, Li X, Lingvay I. Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: a real-world study. J Clin Endocrinol Metab 2023; 108 (04) 920-930
26 Hropot T, Battelino T, Dovc K. Sodium-glucose co-transporter-2 inhibitors in type 1 diabetes: a scoping review. Horm Res Paediatr 2023; 96 (06) 620-630
27 Zheng H, Liu M, Li S. et al. Sodium-glucose co-transporter-2 inhibitors in non-diabetic adults with overweight or obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2021; 12: 706914
28 Cho YK, Kim YJ, Jung CH. Effect of sodium-glucose cotransporter 2 inhibitors on weight reduction in overweight and obese populations without diabetes: a systematic review and a meta-analysis. J Obes Metab Syndr 2021; 30 (04) 336-344
29 Wong J, Chan KY, Lo K. Sodium-glucose co-transporter 2 inhibitors on weight change and cardiometabolic profiles in individuals with overweight or obesity and without diabetes: a meta-analysis. Obes Rev 2021; 22 (12) e13336
30 Cheong AJY, Teo YN, Teo YH. et al. SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials. Obesity (Silver Spring) 2022; 30 (01) 117-128
31 Xing B, Zhao Y, Dong B, Zhou Y, Lv W, Zhao W. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. J Diabetes Investig 2020; 11 (05) 1238-1247
32 Shao SC, Kuo LT, Chien RN, Hung MJ, Lai EC. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews. BMJ Open Diabetes Res Care 2020; 8 (02) e001956
33 Wong C, Yaow CYL, Ng CH. et al. Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver disease in Asian patients with type 2 diabetes: a meta-analysis. Front Endocrinol (Lausanne) 2021; 11: 609135
34 Wei Q, Xu X, Guo L, Li J, Li L. Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne) 2021; 12: 635556
35 Fatima A, Rasool S, Devi S. et al. Exploring the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors: expanding horizons beyond diabetes management. Cureus 2023; 15 (09) e46243
36 Hatanaka T, Ogawa D, Tachibana H. et al. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacol Res Perspect 2016; 4 (04) e00239
37 Tanaka S, Sugiura Y, Saito H. et al. Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. Kidney Int 2018; 94 (05) 912-925
38 Lupsa BC, Kibbey RG, Inzucchi SE. Ketones: the double-edged sword of SGLT2 inhibitors?. Diabetologia 2023; 66 (01) 23-32
39 Tomita I, Kume S, Sugahara S. et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab 2020; 32 (03) 404-419.e6
40 Rahman A, Hitomi H, Nishiyama A. Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure. Hypertens Res 2017; 40 (06) 535-540
41 Tsuboi N, Sasaki T, Okabayashi Y, Haruhara K, Kanzaki G, Yokoo T. Assessment of nephron number and single-nephron glomerular filtration rate in a clinical setting. Hypertens Res 2021; 44 (06) 605-617
42 Kario K, Okada K, Kato M. et al. Twenty-four-hour blood pressure-lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation 2018; 139 (18) 2089-2097
43 Ansary TM, Fujisawa Y, Rahman A. et al. Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats. Sci Rep 2017; 7 (01) 9555
44 Shimizu W, Kubota Y, Hoshika Y. et al; EMBODY trial investigators. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol 2020; 19 (01) 148
45 Herrington WG, Staplin N, Wanner C. et al; The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388 (02) 117-127
46 Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol 2020; 16 (06) 317-336
47 Nishiyama A, Rahman M, Inscho EW. Role of interstitial ATP and adenosine in the regulation of renal hemodynamics and microvascular function. Hypertens Res 2004; 27 (11) 791-804
48 Kidokoro K, Cherney DZI, Bozovic A. et al. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation 2019; 140 (04) 303-315
49 Wakisaka M, Nagao T, Yoshinari M. Sodium glucose cotransporter 2 (SGLT2) plays as a physiological glucose sensor and regulates cellular contractility in rat mesangial cells. PLoS One 2016; 11 (03) e0151585
50 Bae JH, Park EG, Kim S, Kim SG, Hahn S, Kim NH. Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Sci Rep 2019; 9 (01) 13009
51 Kuriyama S. A potential mechanism of cardio-renal protection with sodium-glucose cotransporter 2 inhibitors: amelioration of renal congestion. Kidney Blood Press Res 2019; 44 (04) 449-456
52 Zhang Y, Nakano D, Guan Y. et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int 2018; 94 (03) 524-535
53 Nishiyama A, Kitada K. Possible renoprotective mechanisms of SGLT2 inhibitors. Front Med (Lausanne) 2023; 10: 1115413
54 Umino H, Hasegawa K, Minakuchi H. et al. High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection. Sci Rep 2018; 8 (01) 6791
55 Li J, Liu H, Takagi S. et al. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules. JCI Insight 2020; 5 (06) e129034
56 Pavlou DI, Paschou SA, Anagnostis P. et al. Hypertension in patients with type 2 diabetes mellitus: targets and management. Maturitas 2018; 112: 71-77
57 Zou H, Zhou B, Xu G. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol 2017; 16 (01) 65 Erratum in: Cardiovasc Diabetol. 2018 Mar 9;17 (1):38
58 Blonde L, Umpierrez GE, Reddy SS. et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update. Endocr Pract 2022; 28 (10) 923-1049
59 Stanton RC. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?. Circulation 2014; 129 (05) 542-544
60 Bautista R, Manning R, Martinez F. et al. Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension. Am J Physiol Renal Physiol 2004; 286 (01) F127-F133
61 Kojima N, Williams JM, Takahashi T, Miyata N, Roman RJ. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 2013; 345 (03) 464-472
62 Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjöström CD. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab 2016; 18 (06) 590-597
63 Zhao LM, Zhang M, Zhan ZL, Qiu M. Does combination therapy with SGLT2 inhibitors and renin-angiotensin system blockers lead to greater reduction in cardiorenal events among patients with type 2 diabetes?. Front Cardiovasc Med 2021; 8: 679124
64 Al Rashid S, Elango P, Rahman SZ. SGLT2 inhibitors for cardioprotection. Oman Med J 2023; 38 (04) e521
65 Díaz-Trastoy O, Villar-Taibo R, Sifontes-Dubón M. et al. GLP1 receptor agonist and SGLT2 inhibitor combination: an effective approach in real-world clinical practice. Clin Ther 2020; 42 (02) e1-e12
66 Cheng AYY. Why choose between SGLT2 inhibitors and GLP1-RA when you can use both?: the time to act is now. Circulation 2021; 143 (08) 780-782
67 Zelniker TA, Wiviott SD, Raz I. et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 2019; 139 (17) 2022-2031
68 Mosenzon O, Del Prato S, Schechter M. et al. From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes. Cardiovasc Diabetol 2021; 20 (01) 92
69 Palmer SC, Tendal B, Mustafa RA. et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021; 372: m4573
70 ElSayed NA, Aleppo G, Aroda VR. et al; on behalf of the American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care 2023; 46 (1, suppl 1): S140-S157
71 Nagahisa T, Saisho Y. Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes. Diabetes Ther 2019; 10 (05) 1733-1752
72 McDonagh TA, Metra M, Adamo M. et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42 (36) 3599-3726
73 Kleindorfer DO, Towfighi A, Chaturvedi S. et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke 2021; 52 (07) e364-e467
74 Berg DD, Wiviott SD, Scirica BM. et al. Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus. Circulation 2019; 140 (19) 1569-1577
75 Tsai PC, Chuang WJ, Ko AM. et al. Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials. Cardiovasc Diabetol 2023; 22 (01) 57
76 Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation 2022; 146 (24) 1882-1894
77 Yang YS, Chen HH, Huang CN, Hsu CY, Hu KC, Kao CH. GLP-1RAs for ischemic stroke prevention in patients with type 2 diabetes without established atherosclerotic cardiovascular disease. Diabetes Care 2022; 45 (05) 1184-1192
78 Zhang C, Zhang X, Wang P. et al. Effect of SGLT2 inhibitors on risk of stroke in diabetes: a meta-analysis. Cerebrovasc Dis 2022; 51 (05) 585-593
79 Ceriello A, Lucisano G, Prattichizzo F. et al; AMD Annals study group. The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes. Lancet Reg Health Eur 2023; 31: 100666